BELGIUM – Full-Life Technologies, a Shanghai, China-based radiotherapeutics company, raised USD $63.3M in funding.
The round, which included $47.3M in Series B equity financing and $16M in loan facilities, saw participation from Prosperity7 Ventures and an undisclosed healthcare specialist investor, along with new investors Sky9 Capital, Summer Capital, and GuanghuaWutong Fund, as well as existing shareholders Chengwei Capital, HongShan, and Junson Capital. The financing will advance development of the company’s radiopharmaceutical pipeline and manufacturing capabilities, as well as optimize its proprietary discovery platform, UniRDCTM. With completion of such financing, Full-Life has secured more than $110M funding since its inception in August 2021, including equity financing, loan facilities, and government subsidies.Full-Life Technologies is a global radiotherapeutics company with operations in Belgium, Germany, and China, which seeks to own the entire value chain for radiopharmaceutical research & development, production & commercialization in order to deliver clinical impact for patients. The company plans to attack core issues affecting radiopharmaceuticals today through innovative research that targets the treatments of tomorrow. Since completion of its Series A equity financing in 2022, Full-Life has achieved multiple significant milestones, including but not limited to: 04/01/2024
